Relypsa (Santa Clara, CA) a clinical-stage developer of a therapeutic for hyperkalemia in congestive heart failure patients closed a $10M Series A financing, the final tranche of the $43M round. Participants include 5AM Ventures, New Leaf Partners, Sprout Group, Delphi Ventures, CMEA Ventures and Mediphase Venture Partners.